Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Signaling Network Assessment of Mutations and Copy Number Variations Predict Breast Cancer Subtype-Specific Drug Targets

PROVIDER: PRJNA223171 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR1021650_1.fastq.gz	Fastqsanger.gz
	SRR1021650_2.fastq.gz	Fastqsanger.gz
	SRR1021670_1.fastq.gz	Fastqsanger.gz
	SRR1021670_2.fastq.gz	Fastqsanger.gz
	SRR1021661_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

Affymetrix SNP Data array data of pancreatic cancer PDX models

Project description:Copy number variations were obtained to characterize pancreatic cancer PDX models for tumor research and drug discovery.

2022-02-05 | GSE196183 | GEO

Multi-scale genomic, transcriptomic and proteomic analysis of colorectal cancer cell lines to identify novel biomarkers

Project description:The objective of this study was to measure copy number alterations in a panel of 15 CRC cell lines and relate them to treatment sensitivity. Assessment of copy number variations in a panel of 15 colorectal cancer cell lines

2016-08-23 | E-GEOD-72296 | biostudies-arrayexpress

Copy Number Variations in Genomic Disorders

Project description:Copy Number Variations in Genomic Disorders

| PRJNA75521 | ENA

Homo sapiens

Project description:Copy Number Variations in Genomic Disorders

| PRJNA75523 | ENA

Expression and genomic changes after exposing drug-selected mutants to short term CQ treatment in Plasmodium falciparum.

Project description:Mutations in PfCRT confer chloroquine (CQ) resistance in P. falciparum. Point mutations in the homolog of the mammalian multidrug resistance gene (pfmdr1) can also modulate the levels of CQ response. However, parasites with the same pfcrt and pfmdr1 alleles exhibit a wide range of drug sensitivity, suggesting that additional genes contribute to levels of CQ resistance (CQR). We used 3 isogenic lines which have different drug resistance profiles corresponding to unique mutations in the pfcrt gene (106/1K76, 106/176I, and 106/76I-352K) to study changes in gene expression with and without CQ and genomic variations, i.e. copy number (CN) changes. RNA transcription levels from 45 genes were significantly altered in one or both mutants relative to the parent line. Of particular interest are genes encoding proteins involved in transport and/or regulation of cytoplasmic or compartmental pH, e.g. the V-type H+ pumping pyrophosphatase 2, Ca2+/H+ antiporter VCX1 and copy number changes in pfmdr1. A series of deletion (including 15 genes) also occurred at the beginning of chromosome 10. Keywords: low-dose 3h Chloroquine response, copy number variation

2008-06-26 | GSE10022 | GEO

Drug Synergy Screen and Network Modeling in Dedifferentiated Liposarcoma (DDLS) part 2

Project description:Analysis of DNA copy number variations in two DDLS tumor-derived cell lines DDLS8817 and LPS141 growing in culture in basal conditions The goal of this DNA copy number analysis was to determine if genes used in signaling network modeling in DDLS were amplified or deleted

2013-09-24 | GSE50750 | GEO

Homo sapiens

Project description:Genomic copy number variations in the genomes of leukocytes predict prostate cancer clinical outcomes

| PRJNA289378 | ENA

Homo sapiens

Project description:Oncoscan for HER2 copy number assessment

| PRJNA327412 | ENA

Project description:Preimplantation genetic testing for copy number variations

| PRJNA1116556 | ENA

Identification of signalling pathways downstream of ARHGEF17

Project description:Somatic DNA copy number variations (CNVs) are prevalent in cancer and can drive cancer progression albeit with often uncharacterized roles in altering cell signaling states. We developed a computational approach to predict regulators of signaling from the integrative analysis of genomic and proteomic pan-cancer datasets. Among the predictions, we identified ARHGEF17 to be a regulator of hippo-signaling and performed (phospho)proteomics analysis to test these predictions.

2021-04-06 | PXD021031 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data